Lakefront Biotherapeutics (GLPGF) Capital Leases (2013 - 2017)

Lakefront Biotherapeutics (GLPGF) has reported Capital Leases for 5 consecutive years, with $10596.9 the latest figure, recorded in Q4 2017.

• On a quarterly basis, Capital Leases rose 9.05% year-over-year to $10596.9 in Q4 2017; TTM through Dec 2017 was $10596.9, a 9.05% increase from a year earlier, with the FY2017 full-year figure at $10596.9, up 6.36% from the prior year.
• Capital Leases was $10596.9 for Q4 2017 at Lakefront Biotherapeutics, down from $40683.3 in the prior quarter.
• Over five years, Capital Leases peaked at $227302.0 in Q4 2013 and troughed at $9717.5 in Q4 2016.
• A 5-year average of $74520.2 and a median of $47537.9 in 2016 frame the typical range for Capital Leases.
• Across the five-year window, Capital Leases plunged 85.93% in 2016 and climbed 9.05% in 2017, its largest moves.
• Over 5 years, Capital Leases stood at $227302.0 in 2013, then plunged by 36.77% to $143730.9 in 2014, then sank by 51.96% to $69055.4 in 2015, then sank by 85.93% to $9717.5 in 2016, then increased by 9.05% to $10596.9 in 2017.
• The last three Capital Leases figures came in at $10596.9 (Q4 2017), $40683.3 (Q2 2017), and $53270.3 (Q1 2017), per Business Quant data.